Opioid Litigation Affects All of Pharmacy
Opioid litigation has had a significant impact on the number of pharmacies operating within the United States.
Open Letter to Chief Judge Jon E. DeGuilio
Dr. Joshi writes to Chief Judge Jon DeGuilio requesting an oversight review of the federal prosecutors and judges.
Open Letter to DEA Administrator Milgram
Dr. Joshi writes to Administrator Anne Milgram, urging her to directly oversee the investigation of misconduct by DEA agents.
Burden of Pain, Available May 16th
At long last, Burden of Pain: A Physician's Journey through the Opioid Epidemic is available for sale.
Tell Your Story
Shame affects us in many ways. While always unpleasant, we react to it differently. Most of us run from it....
Bonds That Tie Diseases
Complex chronic diseases may appear to be different. But they're all united by shared patient experiences.
Barby Ingle’s One Pager
We ask chronic pain patient advocate Barby Ingle how she prepares for a clinical encounter.
How We Learn In Medicine
Medical education is concerningly different for practicing physicians compared with medical students.
Faulty Opioid Overdose Data
Initial waves of opioid settlement dollars have been dispensed. Yet we still struggle to define addiction. Unless we refine our...
Lived Experience is Data
Data on addiction and overdoses are notoriously weak. They're subject to varying interpretations. We need to study the lived experiences...
To Be a Chronic Pain Advocate
We share our experiences reaching out to and speaking with federal and state legislators while offering nuggets of advice and...
My Friend, Dr. Ruan
I discuss my growing friendship with Dr. Ruan. It is a bond forged over a united fight for physician rights.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more